NCT01042691 - Isolated Liver Perfusion With Oxaliplatin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions

Unresectable Colorectal Liver Metastases

Interventions

DRUG

Oxaliplatin

The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.

Trial Locations (3)

15213

UPMC Presbyterian, Pittsburgh

15232

UPMC Cancer Centers, Hillman Cancer Center, Pittsburgh

UPMC Shadyside, Pittsburgh